Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
US Department of Justice
Colorcon
Covington
Boehringer Ingelheim
Farmers Insurance
US Army
Accenture
Merck

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,590,530

« Back to Dashboard

Which drugs does patent 8,590,530 protect, and when does it expire?

Patent 8,590,530 protects ONZETRA XSAIL and is included in one NDA.

This patent has forty patent family members in seventeen countries.
Summary for Patent: 8,590,530
Title:Nasal delivery devices
Abstract: A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a container-receiving unit comprising a container chamber for receiving a substance-containing container which contains substance to be delivered to the nasal cavity of the subject, the container chamber including an inlet and an outlet; a nosepiece unit including a nosepiece for fitting to a nasal cavity of the subject and being in fluid communication with the outlet of the container chamber; a mouthpiece unit including a mouthpiece in fluid communication with the inlet of the container chamber and through which the subject in use exhales, such as to entrain substance from the container and deliver the same through the nosepiece; and moisture-mitigation means for mitigating an effect of moisture in an exhaled breath on the entrainment of substance from the container.
Inventor(s): Djupesland; Per Gisle (Oslo, NO), Hafner; Roderick Peter (Wiltshire, GB), Sheldrake; Colin David (Wiltshire, GB)
Assignee: OptiNose AS (Oslo, NO)
Application Number:13/471,146
Patent Claim Types:
see list of patent claims
Delivery; Device; Dosage form; Use;

Drugs Protected by US Patent 8,590,530

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Avanir Pharms ONZETRA XSAIL sumatriptan succinate POWDER;INHALATION 206099-001 Jan 27, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,590,530

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,108,015 Nasal delivery devices ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,590,530

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005283922 ➤ Try a Free Trial
Brazil PI0515289 ➤ Try a Free Trial
Canada 2580217 ➤ Try a Free Trial
Canada 2839080 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Citi
AstraZeneca
Dow
McKinsey
QuintilesIMS
Chubb
Cerilliant
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.